Saturday, July 25, 2026

News

OpenAI Rolls Out ChatGPT Health to All US Users, Europe Still Waiting

ModelsPatryk Raba

OpenAI has expanded ChatGPT Health to all adult users in the United States, linking the chatbot to Apple Health and medical records. Europeans, including Poles, still don't have access because of EU rules on sensitive data.

Contents
  1. What ChatGPT Health Does
  2. Scale of Health Queries
  3. Disclaimers and Legal Context
  4. Why Poland and Europe Are Waiting

As of the week of July 23, 2026, OpenAI is rolling out ChatGPT Health to all signed-in users in the United States who are at least 18 years old. The feature lets people connect the chatbot to Apple Health and select medical record systems, so ChatGPT can analyze test results, medication lists and visit history. The feature has not yet reached Europe.

The feature itself isn't new, OpenAI had been testing it since January as a closed program with a waitlist. This time the company rebuilt it from the ground up and opened it to all adult accounts in the US, regardless of whether someone pays for Plus, Pro, Go or uses the free version of ChatGPT. OpenAI says the rollout will be gradual and should take several weeks to reach all eligible accounts.

What ChatGPT Health Does

Once Apple Health, MyFitnessPal or Function Health is connected, ChatGPT gains visibility into sleep, activity, workout and sensor data. If a user relies on One Medical or a provider connected to Epic or Oracle Health systems, the model can also pull in lab results and appointment history.

The practical use case OpenAI is promoting is comparing new results against previous ones, tracking changes between consultations, and connecting physical activity data with findings from medical tests. Access to records is read-only, the model cannot modify anything in a patient's chart, and users can disconnect any data source at any time.

Scale of Health Queries

OpenAI said the number of health-related queries in ChatGPT has risen from 230 million a week in January to 300 million now. The company notes that 70 percent of such questions come up outside the dedicated health module, meaning in ordinary conversation with the chatbot, which was one of the arguments for building a separate, more tightly secured feature.

OpenAI explicitly states the service is not meant to diagnose or treat any condition, and that its answers require verification by a doctor. That disclaimer is not incidental, the launch came a few weeks after a Florida pastor sued OpenAI, claiming ChatGPT talked him out of seeing a doctor despite symptoms of a pulmonary embolism.

The company stresses that medical data does not go into model training sets and that it works with physicians to refine answers to health questions. That is meant to set ChatGPT Health apart from an ordinary chatbot conversation, where a user might share the same information without any additional safeguards.

Why Poland and Europe Are Waiting

The feature does not work in the European Union, the United Kingdom or Switzerland. The reason is strict sensitive-data rules, including GDPR, which treats health information as a special category of data requiring additional legal grounds for processing. On top of that, European medical record systems, unlike America's Epic or Oracle Health, do not yet have integrations with ChatGPT.

It's a situation similar to the one Apple has been wrestling with for months while rolling out a more advanced Siri in Europe, where EU regulatory requirements routinely push back the launch of new AI features. OpenAI has not given a specific timeline for when ChatGPT Health might arrive outside the United States.

For Polish users, this means that if they want to combine ChatGPT conversations with Apple Health data or test results, they will have to keep doing it manually, pasting in information themselves as before. For companies in the health and medtech sector, it's a signal that integrations with large language models in Europe will require separate, GDPR-compliant solutions rather than a simple import of features from the US market.

Share: